<DOC>
	<DOCNO>NCT02507947</DOCNO>
	<brief_summary>SPECTAmel standardize , quality-assured molecular screening platform tumor characterization storage human biological material ( HBM ) purpose integrate new biomarkers clinical trial optimize access patient therapeutic biomarker-driven clinical trial . HBM clinical/pathological data collect consent patient .</brief_summary>
	<brief_title>SPECTAmel : Screening Patients With Melanoma Tumors Efficient Clinical Trial Access</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Pathologically confirm melanoma stage ( steer committee decide stage include particular time point trial , communicate appropriately participate site ) Mandatory availability adequate human biological material ( HBM ) : FFPE tissue sample primary tumor , recurrent tumor , metastasis , obtain time primary surgery/biopsy ; minimal amount request detailed HBM guideline ; feasible , inclusion sample take recurrence diagnose followup strongly encouraged optional ; Age â‰¥ 18 year ; At least three month lifeexpectancy ; Written inform consent accord ICH/GCP national/local regulation ; Absence active malignancy , except pT12 prostatic cancer Gleason score &lt; 6 , carcinoma situ cervix , 5 year study entry ; Absence exclusion criterion like active hepatitis B/C HIV , second malignancy , severe organ dysfunction comorbidities may prevent inclusion clinical trial . Central confirmation human biological material ( HBM ) adequacy step 2 : Centrally perform confirmation tumor tissue adequacy term quality/ quantity central screening . active hepatitis B/C HIV second malignancy severe organ dysfunction comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>